Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to -$39.0 million.

  • Indivior Pharmaceuticals' Cash from Operations fell 205000.0% to -$39.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.0 million, marking a year-over-year increase of 17224.49%. This contributed to the annual value of $36.0 million for FY2024, which is 11200.0% up from last year.
  • Indivior Pharmaceuticals' Cash from Operations amounted to -$39.0 million in Q3 2025, which was down 205000.0% from $158.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' Cash from Operations' 5-year high stood at $158.0 million during Q2 2025, with a 5-year trough of -$298.0 million in Q4 2023.
  • Over the past 4 years, Indivior Pharmaceuticals' median Cash from Operations value was -$10.0 million (recorded in 2023), while the average stood at -$4.6 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Cash from Operations skyrocketed by 98000.0% in 2024 and then plummeted by 205000.0% in 2025.
  • Indivior Pharmaceuticals' Cash from Operations (Quarter) stood at -$18.0 million in 2022, then plummeted by 1555.56% to -$298.0 million in 2023, then soared by 94.3% to -$17.0 million in 2024, then crashed by 129.41% to -$39.0 million in 2025.
  • Its last three reported values are -$39.0 million in Q3 2025, $158.0 million for Q2 2025, and $75.0 million during Q1 2025.